MCL-803: Efficacy and Safety of Ibrutinib Combined With Venetoclax in the Treatment of Relapsed or Refractory Mantle Cell Lymphoma: A Systematic Review and Single-Arm Meta-Analysis
Department
Internal Medicine
Document Type
Conference Proceeding
Publication Title
Clinical Lymphoma Myeloma and Leukemia
Conference Name
Society of Hematologic Oncology (SOHO) Annual Meeting
Conference Date
2025-09-03 - 2025-09-06
First Page
S854
DOI
10.1016/S2152-2650(25)02477-2
Volume
25
Issue
Supplement 1
Publication Date
9-1-2025
Recommended Citation
Gill, O. A., Sabir, Z., Arshad, H. M., Maqsood, M., Saddique, M. N., Malik, A. A., Ali, M., Raza, M. Z., bin Saleem, H. H., Khawar, M. M., Haider, M. U., Rizwan, D., & Hanif, A. (2025). MCL-803: Efficacy and Safety of Ibrutinib Combined With Venetoclax in the Treatment of Relapsed or Refractory Mantle Cell Lymphoma: A Systematic Review and Single-Arm Meta-Analysis. Clinical Lymphoma Myeloma and Leukemia, 25 (Supplement 1), S854. https://doi.org/10.1016/S2152-2650(25)02477-2
COinS